BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance

Author's Avatar
Apr 02, 2019
Article's Main Image

• Extensive data in pre-clinical models of non-small cell lung cancer (NSCLC) and pancreatic cancer demonstrating AXL's role in reversing tumour-mediated immunosuppression and therapy resistance presented at AACR

• Selective AXL inhibitor, bemcentinib, shown to reverse AXL's effects, thus acting synergistically with immune cells and anti-cancer therapies

• Data further strengthens broad development opportunities for bemcentinib both as a monotherapy, and in combinations, in a broad spectrum of cancers

PR Newswire